Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Pidilizumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 03 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Sep 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.